摘要
Objective:The aim of this study was to investigate the potential ability of medicated serum of Erzhi pills on growth,proliferation and inflammation of the human breast cancer cell line MCF-7 cells.Methods:3-month-old female Sprague–Dawley rats were used to prepared medicated serum,and randomly assigned into four groups:control group(distillated water),low doses(2.25g/kg/d),middle doses(4.5g/kg/d),high does(9.0g/kg/d).The growth curve was meas-ured by MTT method,the proliferation was examined by colony formation assay.Inflam-matory cytokines IL-1β,IL-18 and IL-6 was detected by Quantitative real time polymerase chain reaction(RT-qPCR).Western blot was used to examine the expression of NF-kB signal pathway.Results:The medicated serum of Erzhi pills could inhibit the growth and proliferation of breast cancer cell MCF-7,especially,in the group of middle doses and high does(P<0.05).The protein expression of IKKα,IκBαand p-NF-κB were significantly down regulated.As well as the mRNA expression levels of Inflammatory cytokine,such as IL-1β,IL-18 and IL-6,were decreased.Conclusion:Medicated serum of Erzhi pills played an anti-tumor role in breast cancer via inhibiting the growth and proliferation of MCF-7.Moreover,Erzhi pills could suppress in-flammatory responses from the NFκB signaling pathways,and reduced skeletal muscle pain caused by breast cancer endocrine therapy,and Erzhi pills may be a new target for the treatment of breast cancer.
